Sirius Genomics Receives NRC-IRAP Funding for Development of New Biomarkers

VANCOUVER, Oct. 5 /PRNewswire/ - Sirius Genomics, a developer of companion diagnostics, announced today that it has signed its second Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).

This research funding will be applied to discovery of genomic biomarkers that are predictive of patient response to therapeutics used in critical care medicine leading to improved disease outcomes.

Chris Wagner, President and CEO of Sirius Genomics, comments, "NRC-IRAP's continued support reflects the Canadian Government's commitment to scientific innovation and support for the growth of Canadian companies. Funding from NRC-IRAP will help us advance our pipeline of companion diagnostics."

About Sirius Genomics: www.siriusgenomics.com

Sirius Genomics develops companion diagnostics (CDx) that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.